title: Hemostatic effects of 1 mg daily warfarin on post CABG patients. Post CABG Studies Investigators.
abstract: Although coronary bypass graft surgery has increased the survival and quality of life of many individuals, patients remain at risk of restenosis and thrombotic occlusion of the coronary arteries and bypass grafts. In the screening period for participation in the multicenter Post Coronary Artery Bypass Graft (Post CABG) trial, the effects of 1 mg daily warfarin were evaluated using paired patient samples collected prior to and after at least 21 days of treatment. In stable patients (n = 40; 39 males 1 female; 51-74 years old) who previously had undergone coronary artery revascularization (1-10 years), no alterations in prothrombin time, international normalized ratio (INR), prothrombin fragment 1.2, or the hemostatic risk factors factor VII antigen and coagulant activity, von Willebrand's factor, fibrinogen, tPA, or PAI-1 were associated with the 1 mg daily warfarin treatment. The observations reported here supported the Post CABG Studies Steering Committee decision to treat patients with 1-4 mg warfarin daily adjusted to achieve INRs not to exceed 2. 0 consistent with low-intensity therapy.
authors.affiliation: Loyola University Medical Center, Maywood, Illinois 60153, USA. jwaleng@luc.edu.
authors.forename: J M
authors.initials: JM
authors.lastname: Walenga
authors.forename: D
authors.initials: D
authors.lastname: Hoppensteadt
authors.forename: R
authors.initials: R
authors.lastname: Pifarré
authors.forename: M D
authors.initials: MD
authors.lastname: Cressman
authors.forename: D B
authors.initials: DB
authors.lastname: Hunninghake
authors.forename: N L
authors.initials: NL
authors.lastname: Fox
authors.forename: M L
authors.initials: ML
authors.lastname: Terrin
authors.forename: J L
authors.initials: JL
authors.lastname: Probstfield
mesh_terms: D000368:Aged; D000925:Anticoagulants / Q000008:administration & dosage* / Q000627:therapeutic use; D000941:Antigens / Q000032:analysis; D001026:Coronary Artery Bypass; D005167:Factor VII / Q000032:analysis; D005260:Female; D005340:Fibrinogen / Q000032:analysis; D006801:Humans; D008297:Male; D008875:Middle Aged; D010446:Peptide Fragments / Q000032:analysis; D017395:Plasminogen Activator Inhibitor 1 / Q000097:blood; D011182:Postoperative Care; D011516:Prothrombin / Q000032:analysis; D011517:Prothrombin Time; D012907:Smoking / Q000097:blood; D010959:Tissue Plasminogen Activator / Q000032:analysis; D014859:Warfarin / Q000008:administration & dosage* / Q000627:therapeutic use; D014841:von Willebrand Factor / Q000032:analysis
chemical_list: D000925:Anticoagulants; D000941:Antigens; D010446:Peptide Fragments; D017395:Plasminogen Activator Inhibitor 1; C042580:factor VII clotting antigen; C045879:prothrombin fragment 1.2; D014841:von Willebrand Factor; D014859:Warfarin; D005167:Factor VII; D011516:Prothrombin; D005340:Fibrinogen; D010959:Tissue Plasminogen Activator